about
Feasibility of intensity-modulated radiation therapy in the treatment of advanced cervical chordoma.Automating quality measurement: a system for scalable, comprehensive, and routine care quality assessment.The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleElectronic health records vs Medicaid claims: completeness of diabetes preventive care data in community health centers.International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.Receipt of diabetes preventive care among safety net patients associated with differing levels of insurance coverageBrentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.Insurance continuity and receipt of diabetes preventive care in a network of federally qualified health centers.Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.Automating care quality measurement with health information technology.WIDEN: A tool for medical image management in multicenter clinical trials.Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Comparison of digital tomosynthesis and computed tomography for lung nodule detection in SOS screening program.A Monte Carlo model for cell-cycle kinetics in charged particle irradiation.Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.Correlation between delayed-enhancement magnetic resonance and nitrate myocardial Tc-99m tetrofosmin scintigraphy in myocardial infarction: a case report.Role of (123)I-Iobenguane Myocardial Scintigraphy in Predicting Short-term Left Ventricular Functional Recovery: An Interesting Image.C-C4-04: Development of a Measure Set for Routine, Comprehensive, Automated Assessment of Obesity Care Quality.Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: a myocardial PET study.Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion-metabolism positron emission tomography study.Atorvastatin improves myocardial perfusion in a patient with hypercholesterolemia and single-vessel coronary disease.The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).(18)Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography total glycolytic volume in thymic epithelial neoplasms evaluation: a reproducible image biomarker.Geant4—a simulation toolkitGeant4 developments and applicationsRecent developments in G eant 4Validation of Geant4 Bremsstrahlung models: first resultsEvaluation of phase effects in Geant4 microdosimetry models for particle interactions in waterGeant4 Physics Processes for Microdosimetry Simulation: Design Foundation and Implementation of the First Set of ModelsMicrodosimetry in high-resolution cellular phantoms using the very low energy electromagnetic extension of the Geant4 toolkitModels of biological effects of radiation in the Geant4 ToolkitMonte Carlo Simulation of Electromagnetic Interactions of Radiation with Liquid Water in the Framework of the Geant4-DNA ProjectA powerful simulation tool for medical physics applications: Geant4Reversible inverse mismatch in transient left ventricular apical ballooning: perfusion/metabolism positron emission tomography imagingThe role of PET/CT in the modern treatment of Hodgkin lymphoma
P50
Q33271406-4FE1E8F2-435B-4FFC-9B2C-2359EC884F7CQ33626694-745C42E5-4C1B-4F70-91BD-C63F67619B47Q33696003-5987311E-0336-495D-8942-8CFCAE2B1B7AQ33957609-A7733471-26F1-4A75-9B50-AE2D6C901311Q34334369-68C3D8EC-A24F-426E-A1E4-FA58D1B50D39Q35833693-B8A68C86-DC48-44F6-92AB-CDD60DD1224AQ37216325-BFD5F5B2-3AF3-4CC0-8DBD-16316BDF6DF3Q37315442-1630DD8F-37AA-4BCC-BBB9-2ACF7809EE7EQ37821961-60ED1B66-1463-4BA9-8447-AA63B78046B9Q38024828-5F2DC673-461A-459D-BA71-24F32921EA25Q38202946-77A153F0-CBA8-4A77-BF7D-9650FFFF650FQ38609472-96408847-EC2D-4E74-91F1-03A258748510Q40404841-3C942A2E-9B65-483E-AE5F-9E747999057FQ40462642-F28ABADF-04E8-4F83-B91E-B3D33CE53FE2Q40760001-40A10DFF-7B37-4667-A3F2-11D52A1CCCD2Q41481956-B2B92795-2C02-4C85-919C-013D8A4CC59BQ42852531-2A66DB1E-A04E-4CCF-8E0C-A0D22B6EA854Q43172233-2B498413-26F2-4DA7-89A0-460E4618082DQ45942374-A5158AD8-B6AA-4EDC-A8D4-4A0F45DBDB17Q46264616-7DF5E24E-5AD9-45CD-85FE-65F587CC448EQ46662120-B77393E4-AEC6-4B44-8F20-54C21A1DCE54Q46958565-F7912D71-94A0-42FF-A29F-C1DE8822DE64Q49821096-6182F0AC-3B44-4288-BAD0-CB8AD44C28F7Q51349872-BF1DEBC7-67B6-4BD9-BDEE-4F0FD58A7EC5Q53081422-5F2C2579-EF5A-4CAC-8C39-CCFF305323E1Q56389736-E5BA9106-5E9C-4F0E-8F25-B1D451E7FBF4Q56389770-00929174-8320-4761-BA37-6B374CD6AE55Q56389803-7773008C-8015-46F5-B845-2C17BF5A1E63Q59673232-F188F430-6B5D-482A-9088-0D5517F7C5A8Q61509545-EED2BCB0-83FB-421B-BF80-81F40DD400ABQ61509547-7FFC01BB-840B-4F7C-88E8-40981DA4AA6FQ61509551-56E12210-5D73-4B1B-9044-094FB6058508Q61509557-9A8E0E7C-B6FB-4074-9941-608EF6E2AD43Q61509560-EF738CDB-3C1B-461B-A61A-9EDF2311EFD5Q61509933-E8B9A233-0654-4411-9EAB-659BB4E3868AQ80139658-2A6032FD-10D4-43A9-8347-E9071C793334Q91512311-F47CB1DB-4FB1-42AE-81F5-E5A711B1746A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stéphane Chauvie
@ast
Stéphane Chauvie
@en
Stéphane Chauvie
@es
Stéphane Chauvie
@nl
Stéphane Chauvie
@sl
type
label
Stéphane Chauvie
@ast
Stéphane Chauvie
@en
Stéphane Chauvie
@es
Stéphane Chauvie
@nl
Stéphane Chauvie
@sl
prefLabel
Stéphane Chauvie
@ast
Stéphane Chauvie
@en
Stéphane Chauvie
@es
Stéphane Chauvie
@nl
Stéphane Chauvie
@sl
P106
P1153
8782461800
P21
P31
P496
0000-0003-4394-5031